Jubilant Ingrevia Ltd

- The company had incurred a capital expenditure of Rs. 572 Cr in FY24 and plans to spend about Rs. 600-700 Cr in FY25 as part of the ongoing Rs. 2,000 Cr capex plan. - Despite high capex, the company limited borrowings and actually decreased net debt by Rs. 48 Cr during the second half of FY24 via working capital optimization. - Net debt as of March 31, 2024, stood at Rs. 653 Cr with a net debt to EBITDA ratio of 1.43 times. - There is no explicit mention of any immediate or planned new fundraising through debt or equity in the transcript. - The company may increase capex slightly beyond planned Rs. 600 Cr if long-term contracts with customers are signed, but no direct reference to raising new funds was made.

- Rs. 2,000 Crores capex plan announced over FY '22 to FY '25, with Rs. 1,400 Cr already committed and remaining Rs. 600-700 Cr to be spent mainly in FY '25. - FY '25 capex includes investments in Food and Cosmetic Grade Niacinamide plant, new food grade choline (CC/CBT) plant, and expansion of GMP facilities for CDMO business. - Future capex beyond FY '25 expected around Rs. 400-500 Cr per annum focusing on areas aligned with strategic priorities: Agrochemical expansions, diketene derivatives (Phase 3 and 4), microbial segment plants, and human nutrition premixes. - New multipurpose Agro Active & Intermediate plant commissioned at Bharuch. New Diketene Derivatives plant commissioned at Gajraula. - A GMP-compliant facility for Food & Cosmetic grade B3 is expected to be commissioned in Q3 FY '25. - Additional capex may be required (Rs. 1,500-2,000 Cr) for achieving 3x revenue growth beyond the original plan. - Capex investments are only approved with internal criteria of >20% EBITDA margin and >20% ROCE.

- Specialty Chemical business expected to grow 3 to 3.5 times over next 3 years, constituting at least 60% of overall business. - Growth to be driven by CDMO, fine chemical business (pyridine and diketene derivatives), and Microbial Solutions. - CDMO segment seeing increasing inquiries, including semiconductors, with potential for rapid volume growth once product approvals occur. - Nutrition business volumes are steady and growing; vitamin B3 global market share increased in FY24 despite pricing pressures. - Company targets revenue potential of around Rs. 8,000 crores post ongoing capex investments. - Continued focus on customer-centricity and ramping up newly commissioned plants. - Anticipated top-line growth aligned with “Pinnacle 345” strategy aiming for 3x revenue and 4x EBITDA in 5 years. - Capex plans beyond FY25 indicate further expansion with Rs. 400-500 crores per annum to support 3x revenue growth from current baseline.

- Jubilant Ingrevia targets a bold 5-year growth strategy called Pinnacle 345 aiming for 3x revenue and 4x EBITDA growth. - Steady-state overall EBITDA margins are expected to exceed 20%, with specialty chemicals margin higher than this benchmark. - Specialty chemical business margins are projected at 17-18% currently, improving to above 20% in 3-4 years as the specialty mix grows from ~40-50% to 60-70%. - The company expects a steady-state EBITDA margin north of 20% driven by specialty chemicals and nutrition segments with optimized operations. - Net profit (PAT) took a hit in FY24 (Rs. 183 Cr vs Rs. 308 Cr in FY23) due to pricing pressure but is expected to improve with margin expansion and volume growth. - Capex plans of Rs. 2,000 Cr over FY22-25 plus additional Rs. 1,500-2,000 Cr beyond FY25 aim to drive revenue towards Rs. 8,000 Cr, supporting strong growth in earnings going forward. - New high-potential specialty products including CDMO (contract development and manufacturing) and nutrition areas are key future profit drivers.

- Jubilant Ingrevia has a full potential roadmap/visibility to at least Rs. 8,000 crores in orderbook or pending orders. - This outlook is based on the capex and growth plans they have executed and those planned in the current fiscal year. - The company has committed Rs. 1,400 crores of a Rs. 2,000 crore capex over the past 2-3 years, with remaining Rs.600 crores planned for this fiscal. - Some opportunities are identified but pending formal capex approval (e.g., CC/CBT specialty nutrition and GMP-3 for CDMO business). - Large customer contracts and long-term arrangements may increase this capex/order pipeline beyond Rs. 600 crores currently planned this year. - The business mix and new plant commissioning, especially in specialty chemicals and nutrition segments, support strong order inflow visibility.